GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R&D chief told Fierce to “stay tuned” for the company’s own data. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results